Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Pharma
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
HARMONi-6 marks the first phase 3 trial in which a regimen has beaten the combination of a PD-1 inhibitor and chemotherapy on PFS in first-line NSCLC.
Angus Liuu
Oct 19, 2025 10:45am
FDA approves Regeneron's Libtayo for adjuvant use in CSCC
Oct 9, 2025 11:00am
Junshi, Coherus move Loqtorzi closer to another approval
Jun 12, 2024 11:45am
Summit and Akeso deliver Keytruda-topping results in NSCLC
May 31, 2024 11:00am
Merck's Keytruda misses the mark in endometrial cancer study
May 9, 2024 10:55am
Merck's Keytruda improves survival in cervical cancer trial
Mar 15, 2024 11:31am
